Difference between revisions of "Talk:Moderna"
m (t) |
|||
(2 intermediate revisions by 2 users not shown) | |||
Line 3: | Line 3: | ||
.https://www.bloomberg.com/features/2020-moderna-biontech-covid-shot/ | .https://www.bloomberg.com/features/2020-moderna-biontech-covid-shot/ | ||
− | =Rumours | + | =Rumours= |
There are strong rumours about the Pierre-Elliott-Trudeau Foundation owning a 40% stake in private company Acuitas | There are strong rumours about the Pierre-Elliott-Trudeau Foundation owning a 40% stake in private company Acuitas | ||
Line 19: | Line 19: | ||
[12] In August 2016, Arbutus realized that the Acuitas-Moderna sub-license was a target license for Influenza A. Arbutus deemed the granting of a target license to be in breach of its agreement with Acuitas. | [12] In August 2016, Arbutus realized that the Acuitas-Moderna sub-license was a target license for Influenza A. Arbutus deemed the granting of a target license to be in breach of its agreement with Acuitas. | ||
""" | """ | ||
+ | |||
+ | :Stem cell research involves experimentation with embryos, right? Sensitive topic. You may want to use the sign off shortcut: "<nowiki>~~~~</nowiki>", this produces something like: [[User:Urban|Urban]] ([[User talk:Urban|talk]]) 03:02, 18 February 2022 (UTC) |
Latest revision as of 03:04, 18 February 2022
A link I found about stem cell therapy used in COVID vaccine
.https://www.bloomberg.com/features/2020-moderna-biontech-covid-shot/
Rumours
There are strong rumours about the Pierre-Elliott-Trudeau Foundation owning a 40% stake in private company Acuitas
David Martin https://rumble.com/vupkuv-breaking-criminal-canadian-monopoly-dr.-david-martin-exposes-why-trudeau-wo.html
Robert W Malone https://rumble.com/vv4dz3-trudeaus-foundation-may-hold-40-ownership-of-acuitas-which-makes-mechanic-l.html
Both Acuitas and Arbutus got into a legal scuffle that was decided in favour or Arbutus... the legal wrangle stopped there so the two might have come to an agreement after the decision.
In the court decision https://www.canlii.org/en/bc/bcsc/doc/2017/2017bcsc199/2017bcsc199.html """ [11] Acuitas was required to give notice of the grant of any sub-licenses. Acuitas did so in May, 2015, when it advised Arbutus of a sub-license granted to Moderna Therapeutics (“Moderna”). Arbutus was in the midst of a merger and did not pay much attention to the sub-license. Arbutus received royalty payments as called for in the cross-license agreement. [12] In August 2016, Arbutus realized that the Acuitas-Moderna sub-license was a target license for Influenza A. Arbutus deemed the granting of a target license to be in breach of its agreement with Acuitas. """